Biotech News

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

Alkermes plc (ALKS)Alkermes plc2026-10-30 11:00 ESTClinical readout

— Proof-of-Concept Study to Evaluate Effects of Orexin 2 Receptor Agonist on Symptoms of Depression in Adults With and Without Excessive Daytime Sleepiness — DUBLIN --(BUSINESS WIRE)--Oct. 30, 2026-- Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the

Related news

ALKSAlkermes plc2026-09-21 11:00 EST

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

ALKSAlkermes plc2026-10-13 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

VTGNVistagen Therapeutics, Inc.2026-09-22 12:30 EST

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

ANNXAnnexon, Inc.2026-10-28 12:01 EST

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-11-05 12:00 EST

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

ALKSAlkermes plc2026-11-03 12:05 EST

Alkermes plc Reports Third Quarter 2026 Financial Results

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Stock data

Close: 44.54 USD
Market cap: 6.89B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States